Keywords: ایمگلوسراز; Gaucher; Imiglucerase; Substrate reduction therapy;
مقالات ISI ایمگلوسراز (ترجمه نشده)
مقالات زیر هنوز به فارسی ترجمه نشده اند.
در صورتی که به ترجمه آماده هر یک از مقالات زیر نیاز داشته باشید، می توانید سفارش دهید تا مترجمان با تجربه این مجموعه در اسرع وقت آن را برای شما ترجمه نمایند.
در صورتی که به ترجمه آماده هر یک از مقالات زیر نیاز داشته باشید، می توانید سفارش دهید تا مترجمان با تجربه این مجموعه در اسرع وقت آن را برای شما ترجمه نمایند.
Keywords: ایمگلوسراز; DD; Gaucher disease; ERT; enzyme replacement therapy; FDA; Food and Drug Administration; AST; aspartate aminotransferase; ALT; alanine aminotransferase; SOC; System Organ Classification; Gaucher disease; Lysosomal storage diseases; Enzyme replacement ther
Keywords: ایمگلوسراز; Enfermedad; Gaucher; Embarazo; Imiglucerasa; Terapia de reemplazo; Disease; Gaucher; Pregnancy; Imiglucerase; Replacement therapy;
Stability is maintained in adults with Gaucher disease type 1 switched from velaglucerase alfa to eliglustat or imiglucerase: A sub-analysis of the eliglustat ENCORE trial
Keywords: ایمگلوسراز; Composite endpoint; Eliglustat; Gaucher disease type 1; Imiglucerase; Non-inferiority trial; Velaglucerase alfa;
A Phase 3, multicenter, open-label, switchover trial to assess the safety and efficacy of taliglucerase alfa, a plant cell-expressed recombinant human glucocerebrosidase, in adult and pediatric patients with Gaucher disease previously treated with imigluc
Keywords: ایمگلوسراز; Gaucher disease; Enzyme replacement therapy; Taliglucerase alfa; Imiglucerase;
Development and application to clinical practice of a validated HPLC method for the analysis of β-glucocerebrosidase in Gaucher disease
Keywords: ایمگلوسراز; GD; Gaucher disease; GBA; β-glucocerebrosidase; GlcCer; glucocerebroside; FACS; fluorescence-activated cell sorter; PNP-Glc; 4-nitrophenyl-β-d-glucopyranoside; PNP; p-nitrophenol; ERT; enzyme replacement therapy; IMG; imiglucerase; EMA; European Medicin
Booster-effect with velaglucerase alfa in patients with Gaucher disease switched from long-term imiglucerase therapy: Early Access Program results from Jerusalem
Keywords: ایمگلوسراز; Gaucher disease; Enzyme replacement therapy; Imiglucerase; Velaglucerase alfa; Switch-over
The management of pregnancy in Gaucher disease
Keywords: ایمگلوسراز; Gaucher disease; Imiglucerase; Pregnancy; Delivery; Enzyme replacement therapy
Osteopenia in Gaucher disease develops early in life: Response to imiglucerase enzyme therapy in children, adolescents and adults
Keywords: ایمگلوسراز; BMD, bone mineral density; DXA, dual energy X-ray absorptiometry; GBA1, acid-β-glucosidase; GD, Gaucher disease; GD1, type 1 Gaucher disease; ICGG, International Collaborative Gaucher Group; SD, standard deviationGaucher disease; Osteopenia; Imiglucerase;
Development of a panel of highly sensitive, equivalent assays for detection of antibody responses to velaglucerase alfa or imiglucerase enzyme replacement therapy in patients with Gaucher disease
Keywords: ایمگلوسراز; ADA; anti-drug antibody; BSA; bovine serum albumin; CPM; counts per minute; DPBS; Dulbecco's Phosphate Buffered Saline solution; ECL; electrochemiluminescence; EMA; European Medicines Agency; FDA; Food and Drug Administration; HBS-EP; HEPES-buffered salin
Baseline characteristics and outcome in Romanian patients with Gaucher disease type 1
Keywords: ایمگلوسراز; Gaucher disease type 1; Imiglucerase; Outcome
A randomized trial comparing the efficacy and safety of imiglucerase (Cerezyme) infusions every 4 weeks versus every 2 weeks in the maintenance therapy of adult patients with Gaucher disease type 1
Keywords: ایمگلوسراز; Enzyme replacement therapy; Gaucher disease; Glucocerebrosidase; Glucosylceramide β-glucosidase; Imiglucerase; Infusion frequency; Type 1;
Étude rétrospective sur dix ans des patients atteints de maladie de Gaucher au CHU de Rennes
Keywords: ایمگلوسراز; Maladie de Gaucher; Gammapathie monoclonale; Syndrome parkinsonien; Imiglucérase; MiglustatGaucher's disease; Monoclonal gammopathy; Parkinsonism; Imiglucerase; Miglustat